DK2812434T3 - Agonister og antagonister af toll-lignende receptor-13 (tlr-13) - Google Patents

Agonister og antagonister af toll-lignende receptor-13 (tlr-13) Download PDF

Info

Publication number
DK2812434T3
DK2812434T3 DK13708667.4T DK13708667T DK2812434T3 DK 2812434 T3 DK2812434 T3 DK 2812434T3 DK 13708667 T DK13708667 T DK 13708667T DK 2812434 T3 DK2812434 T3 DK 2812434T3
Authority
DK
Denmark
Prior art keywords
seq
rna
tlr13
rrna
tlr
Prior art date
Application number
DK13708667.4T
Other languages
English (en)
Inventor
Stefan Bauer
Hubertus Hochrein
Carsten Kirschning
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK2812434T3 publication Critical patent/DK2812434T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (12)

1. RNA, der består af sekvensen valgt fra gruppen, der består af SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 og SEQ ID NO: 12, til anvendelse som et farmaceutisk middel.
2. RNA ifølge krav 1 til anvendelse som et farmaceutisk middel til aktivering af Toll-lignende receptor-13 (TLR-13).
3. RNA ifølge krav 1 til anvendelse som et farmaceutisk middel til aktivering af Toll-lignende receptor-13 (TLR-13)-udtrykkende celler hos et individ.
4. RNA ifølge krav 1 til anvendelse som et farmaceutisk middel til stimulering af et immunrespons hos et ikke-primat individ.
5. RNA ifølge krav 1, hvor det farmaceutiske middel er et immunstimulerende middel.
6. RNA ifølge krav 1, hvor det farmaceutiske middel er et adjuvans, fortrinsvis til anvendelse til vaccinering mod bakterieinfektion.
7. RNA ifølge et hvilket som helst af ovennævnte krav til anvendelse som et farmaceutisk middel til behandling af en infektion med en grampositiv eller gramnegativ bakterie, der er resistent over for et eller flere anitbiotikum/antibiotika fra macrolid-, lincosamid- og streptogramin (MLS)-gruppen.
8. RNA ifølge krav 7 til anvendelse som et farmaceutisk middel til behandling af en infektion med en grampositiv eller gramnegativ bakterie, der er resistent over for erythromycin, fortrinsvis til behandling af en infektion med en grampositiv bakterie, der er resistent over for erythromycin, mere fortrinsvis til behandling af en infektion med Staphylococcus aureus eler Streptococcus pneumonia.
9. Farmaceutisk sammensætning, der omfatter et RNA ifølge krav 1, til anvendelse som et farmaceutisk middel.
10. Farmaceutisk sammensætning ifølge krav 9 til anvendelse som et farmaceutisk middel til aktivering af Toll-lignende receptor-13 (TLR-13).
11. Farmaceutisk sammensætning ifølge krav 9 til anvendelse som et farmaceutisk middel til aktivering af Toll-lignende receptor-13 (TLR-13)-udtrykkende celler hos et individ.
12. Farmaceutisk sammensætning ifølge krav 9 til anvendelse som et farmaceutisk middel til stimulering af et immunrespons hos et ikke-primat individ.
DK13708667.4T 2012-02-09 2013-02-08 Agonister og antagonister af toll-lignende receptor-13 (tlr-13) DK2812434T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261597063P 2012-02-09 2012-02-09
PCT/EP2013/000392 WO2013117348A1 (en) 2012-02-09 2013-02-08 Agonists and antagonists of toll-like receptor (tlr) 13

Publications (1)

Publication Number Publication Date
DK2812434T3 true DK2812434T3 (da) 2018-07-16

Family

ID=47845891

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13708667.4T DK2812434T3 (da) 2012-02-09 2013-02-08 Agonister og antagonister af toll-lignende receptor-13 (tlr-13)

Country Status (4)

Country Link
US (1) US9556439B2 (da)
EP (1) EP2812434B1 (da)
DK (1) DK2812434T3 (da)
WO (1) WO2013117348A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2812434B1 (en) * 2012-02-09 2018-03-28 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (tlr) 13
EP2847215A1 (en) * 2012-05-07 2015-03-18 Synthes GmbH Methods and devices for treating intervertebral disc disease
US20170137820A1 (en) * 2014-08-06 2017-05-18 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (tlr) 13

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526688A (ja) 1997-05-19 2001-12-18 メルク エンド カンパニー インコーポレーテッド オリゴヌクレオチドアジュバント
EP1238071B1 (en) * 1999-11-29 2008-04-23 Avi Biopharma, Inc. Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s rrnas and their uses
EP1268774A2 (en) 2000-03-21 2003-01-02 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
EP1366077B1 (en) * 2000-09-15 2011-05-25 Coley Pharmaceutical GmbH PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
NZ535952A (en) * 2002-04-04 2009-01-31 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US8623353B1 (en) * 2003-09-23 2014-01-07 Technische Universitat Munchen TLR2 antagonistic antibody and use thereof
US7838658B2 (en) * 2005-10-20 2010-11-23 Ian Maclachlan siRNA silencing of filovirus gene expression
CA2648585C (en) * 2006-04-07 2017-07-25 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
EP2200638B1 (en) * 2007-10-09 2016-03-16 The University of Melbourne Compositions for the transfection of cells
US9090897B2 (en) * 2009-12-18 2015-07-28 Bavarian Nordic A/S Production of IFN-lambda by conventional dendritic cells
EP2812434B1 (en) * 2012-02-09 2018-03-28 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (tlr) 13

Also Published As

Publication number Publication date
WO2013117348A1 (en) 2013-08-15
EP2812434A1 (en) 2014-12-17
EP2812434B1 (en) 2018-03-28
US9556439B2 (en) 2017-01-31
US20140377309A1 (en) 2014-12-25
WO2013117348A8 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
Tartey et al. Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells
Vollmer et al. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll‐like receptor 9 dependent T helper type 2 biased immune stimulation
Rad et al. Extracellular and intracellular pattern recognition receptors cooperate in the recognition of Helicobacter pylori
de Zoete et al. Activation of human and chicken toll-like receptors by Campylobacter spp
CN118147029A (zh) 工程化的免疫刺激性细菌菌株及其用途
Lipford et al. Poly‐guanosine motifs costimulate antigen‐reactive CD8 T cells while bacterial CpG‐DNA affect T‐cell activation via antigen‐presenting cell‐derived cytokines
CN112245568B (zh) E184l基因缺失减毒非洲猪瘟病毒株的构建及其作为疫苗的应用
KR101927726B1 (ko) 살모넬라균의 비코딩 rna 및 이의 식별과 응용
CN103547675A (zh) 免疫刺激性寡脱氧核苷酸
CN103547674A (zh) 免疫刺激性寡脱氧核苷酸
Lagos et al. Characterization and vaccine potential of membrane vesicles produced by Francisella noatunensis subsp. orientalis in an adult zebrafish model
Felgner et al. The immunogenic potential of bacterial flagella for Salmonella‐mediated tumor therapy
Zelenay et al. Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides
Spiller et al. Cellular recognition of trimyristoylated peptide or enterobacterial lipopolysaccharide via both TLR2 and TLR4
Bakkemo et al. Intracellular localisation and innate immune responses following Francisella noatunensis infection of Atlantic cod (Gadus morhua) macrophages
Choo et al. TLR sensing of bacterial spore-associated RNA triggers host immune responses with detrimental effects
EP2812434B1 (en) Agonists and antagonists of toll-like receptor (tlr) 13
Rajashekara et al. Genomic island 2 of Brucella melitensis is a major virulence determinant: functional analyses of genomic islands
US20190100756A1 (en) CpG-OLIGODEOXYNUCLEOTIDE, IMMUNOGENIC COMPOSITION INCLUDING THE SAME, AND METHOD OF INDUCING IMMUNE RESPONSE BY THE SAME
Liu et al. Identification and analysis of the immune effects of CpG motifs that protect Japanese flounder (Paralichthys olivaceus) against bacterial infection
Häcker Chlamydia in pigs: intriguing bacteria associated with sub-clinical carriage and clinical disease, and with zoonotic potential
Kim et al. Efficacy of a recombinant M-like protein, SimA as a subunit vaccine candidate against Streptococcus parauberis infection in olive flounder, Paralichthys olivaceus
Tanaka et al. Toll-like receptor 9-dependent activation of bone marrow-derived dendritic cells by URA5 DNA from Cryptococcus neoformans
US20170137820A1 (en) Agonists and antagonists of toll-like receptor (tlr) 13
Damke et al. Helicobacter pylori provokes STING immunosurveillance via trans-kingdom conjugation